Table of Contents
Journal of Amino Acids
Volume 2015 (2015), Article ID 973548, 13 pages
http://dx.doi.org/10.1155/2015/973548
Review Article

Endotoxin-Induced Tryptophan Degradation along the Kynurenine Pathway: The Role of Indolamine 2,3-Dioxygenase and Aryl Hydrocarbon Receptor-Mediated Immunosuppressive Effects in Endotoxin Tolerance and Cancer and Its Implications for Immunoparalysis

Institute of Genome Biology, Leibniz Institute for Farm Animal Biology, Germany

Received 28 August 2015; Revised 28 October 2015; Accepted 6 December 2015

Academic Editor: Mario Herrera-Marschitz

Copyright © 2015 Elisa Wirthgen and Andreas Hoeflich. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Mándi and L. Vécsei, “The kynurenine system and immunoregulation,” Journal of Neural Transmission, vol. 119, no. 2, pp. 197–209, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. O. Takikawa, “Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism,” Biochemical and Biophysical Research Communications, vol. 338, no. 1, pp. 12–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. D. H. Munn, M. Zhou, J. T. Attwood et al., “Prevention of allogeneic fetal rejection by tryptophan catabolism,” Science, vol. 281, no. 5380, pp. 1191–1193, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. X. Liu, R. C. Newton, S. M. Friedman, and P. A. Scherle, “Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy,” Current Cancer Drug Targets, vol. 9, no. 8, pp. 938–952, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Huttunen, J. Syrjänen, J. Aittoniemi et al., “High activity of indoleamine 2, 3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients,” Shock, vol. 33, no. 2, pp. 149–154, 2010. View at Google Scholar · View at Scopus
  6. P. Tattevin, D. Monnier, O. Tribut et al., “Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock,” Journal of Infectious Diseases, vol. 201, no. 6, pp. 956–966, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Erhardt, L. Schwieler, L. Nilsson, K. Linderholm, and G. Engberg, “The kynurenic acid hypothesis of schizophrenia,” Physiology & Behavior, vol. 92, no. 1-2, pp. 203–209, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. G. J. Guillemin, K. R. Williams, D. G. Smith, G. A. Smythe, J. Croitoru-Lamoury, and B. J. Brew, “Quinolinic acid in the pathogenesis of Alzheimer's disease,” in Developments in Tryptophan and Serotonin Metabolism, pp. 167–176, Springer, Berlin, Germany, 2003. View at Google Scholar
  9. J. C. O'Connor, M. A. Lawson, C. André et al., “Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice,” Molecular Psychiatry, vol. 14, no. 5, pp. 511–522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Dantzer, J. C. O'Connor, M. A. Lawson, and K. W. Kelley, “Inflammation-associated depression: from serotonin to kynurenine,” Psychoneuroendocrinology, vol. 36, no. 3, pp. 426–436, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. R. Moffett and M. A. Namboodiri, “Tryptophan and the immune response,” Immunology and Cell Biology, vol. 81, no. 4, pp. 247–265, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Peters, “Tryptophan nutrition and metabolism: an overview,” in Kynurenine and Serotonin Pathways, pp. 345–358, Springer, 1991. View at Google Scholar
  13. R. S. Grant, H. Naif, M. Espinosa, and V. Kapoor, “IDO induction in IFN-γ activated astroglia: a role in improving cell viability during oxidative stress,” Redox Report, vol. 5, no. 2-3, pp. 101–104, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Gonzalez, N. Varo, E. Alegre, A. Diaz, and I. Melero, “Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach,” Advances in Clinical Chemistry, vol. 45, pp. 155–197, 2008. View at Google Scholar
  15. J. P. Ruddick, A. K. Evans, D. J. Nutt, S. L. Lightman, G. A. W. Rook, and C. A. Lowry, “Tryptophan metabolism in the central nervous system: medical implications,” Expert Reviews in Molecular Medicine, vol. 8, no. 20, pp. 1–27, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. T. W. Stone and L. G. Darlington, “Endogenous kynurenines as targets for drug discovery and development,” Nature Reviews Drug Discovery, vol. 1, no. 8, pp. 609–620, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Wang, H. Liu, G. McKenzie et al., “Kynurenine is an endothelium-derived relaxing factor produced during inflammation,” Nature Medicine, vol. 16, no. 3, pp. 279–285, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Moroni, A. Cozzi, M. Sili, and G. Mannaioni, “Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery,” Journal of Neural Transmission, vol. 119, no. 2, pp. 133–139, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. G. F. Oxenkrug, “Increased plasma levels of xanthurenic and kynurenic acids in type 2 diabetes,” Molecular Neurobiology, vol. 52, no. 2, pp. 805–810, 2015. View at Publisher · View at Google Scholar
  20. A. Pérez-González, J. R. Alvarez-Idaboy, and A. Galano, “Free-radical scavenging by tryptophan and its metabolites through electron transfer based processes,” Journal of Molecular Modeling, vol. 21, article 213, 2015. View at Publisher · View at Google Scholar
  21. V. Chobot, F. Hadacek, W. Weckwerth, and L. Kubicova, “Iron chelation and redox chemistry of anthranilic acid and 3-hydroxyanthranilic acid: a comparison of two structurally related kynurenine pathway metabolites to obtain improved insights into their potential role in neurological disease development,” Journal of Organometallic Chemistry, vol. 782, pp. 103–110, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. L. G. Darlington, C. M. Forrest, G. M. Mackay et al., “On the biological importance of the 3-hydroxyanthranilic acid: anthranilic acid ratio,” International Journal of Tryptophan Research, vol. 3, no. 1, pp. 51–59, 2010. View at Google Scholar · View at Scopus
  23. D. Krause, H.-S. Suh, L. Tarassishin et al., “The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1,” The American Journal of Pathology, vol. 179, no. 3, pp. 1360–1372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. W. Taylor and G. Feng, “Relationship between interferon-γ, indoleamine 2, 3-dioxygenase, and tryptophan catabolism,” The FASEB Journal, vol. 5, no. 11, pp. 2516–2522, 1991. View at Google Scholar · View at Scopus
  25. S. R. Thomas and R. Stocker, “Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway,” Redox Report, vol. 4, no. 5, pp. 199–220, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Le Floc'h, W. Otten, and E. Merlot, “Tryptophan metabolism, from nutrition to potential therapeutic applications,” Amino Acids, vol. 41, no. 5, pp. 1195–1205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. N. J. C. King and S. R. Thomas, “Molecules in focus: indoleamine 2,3-dioxygenase,” The International Journal of Biochemistry and Cell Biology, vol. 39, no. 12, pp. 2167–2172, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Ohira, H. Hagihara, K. Toyama et al., “Expression of tryptophan 2,3-dioxygenase in mature granule cells of the adult mouse dentate gyrus,” Molecular Brain, vol. 3, no. 1, article 26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Kanai, T. Nakamura, and H. Funakoshi, “Identification and characterization of novel variants of the tryptophan 2, 3-dioxygenase gene: differential regulation in the mouse nervous system during development,” Neuroscience Research, vol. 64, no. 1, pp. 111–117, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. H. J. Ball, H. J. Yuasa, C. J. D. Austin, S. Weiser, and N. H. Hunt, “Indoleamine 2, 3-dioxygenase-2; a new enzyme in the kynurenine pathway,” The International Journal of Biochemistry and Cell Biology, vol. 41, no. 3, pp. 467–471, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. H. J. Ball, A. Sanchez-Perez, S. Weiser et al., “Characterization of an indoleamine 2, 3-dioxygenase-like protein found in humans and mice,” Gene, vol. 396, no. 1, pp. 203–213, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Löb, A. Königsrainer, D. Zieker et al., “IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism,” Cancer Immunology, Immunotherapy, vol. 58, no. 1, pp. 153–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. L. M. F. Merlo, E. Pigott, J. B. DuHadaway et al., “IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis,” The Journal of Immunology, vol. 192, no. 5, pp. 2082–2090, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Metz, C. Smith, J. B. DuHadaway et al., “IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation,” International Immunology, vol. 26, no. 7, pp. 357–367, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Bohár, J. Toldi, F. Fülöp, and L. Vécsei, “Changing the face of kynurenines and neurotoxicity: therapeutic considerations,” International Journal of Molecular Sciences, vol. 16, no. 5, pp. 9772–9793, 2015. View at Publisher · View at Google Scholar
  36. S. Lancellotti, L. Novarese, and R. De Cristofaro, “Biochemical properties of indoleamine 2,3-dioxygenase: from structure to optimized design of inhibitors,” Current Medicinal Chemistry, vol. 18, no. 15, pp. 2205–2214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Yoshida, T. Nukiwa, Y. Watanabe, M. Fujiwara, F. Hirata, and O. Hayaishi, “Regulation of indoleamine 2,3-dioxygenase activity in the small intestine and the epididymis of mice,” Archives of Biochemistry and Biophysics, vol. 203, no. 1, pp. 343–351, 1980. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Yoshida, J. Imanishi, T. Oku, T. Kishida, and O. Hayaishi, “Induction of pulmonary indoleamine 2,3-dioxygenase by interferon,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 1, pp. 129–132, 1981. View at Publisher · View at Google Scholar · View at Scopus
  39. E. T. Reitschel, T. Kirikae, F. U. Shade et al., “Bacterial endotoxin: molecular relationships of structure to activity and function,” The FASEB Journal, vol. 8, no. 2, pp. 217–225, 1994. View at Google Scholar · View at Scopus
  40. S. N. Vogel and M. M. Hogan, Role of Cytokines in Endotoxin-Mediated Host Responses, Oxford University Press, New York, NY, USA, 1990.
  41. R. P. Darveau, T.-T. T. Pham, K. Lemley et al., “Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4,” Infection and Immunity, vol. 72, no. 9, pp. 5041–5051, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. S. M. Dauphinee and A. Karsan, “Lipopolysaccharide signaling in endothelial cells,” Laboratory Investigation, vol. 86, no. 1, pp. 9–22, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. D. J. Kahler and A. L. Mellor, “T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase,” in Dendritic Cells, vol. 188 of Handbook of Experimental Pharmacology, pp. 165–196, Springer, Berlin, Germany, 2009. View at Publisher · View at Google Scholar
  44. H. L. Pahl, “Activators and target genes of Rel/NF-κB transcription factors,” Oncogene, vol. 18, no. 49, pp. 6853–6866, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. U. M. Litzenburger, C. A. Opitz, F. Sahm et al., “Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR,” Oncotarget, vol. 5, no. 4, pp. 1038–1051, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. H. J. Yuasa, M. Takubo, A. Takahashi, T. Hasegawa, H. Noma, and T. Suzuki, “Evolution of vertebrate indoleamine 2,3-dioxygenases,” Journal of Molecular Evolution, vol. 65, no. 6, pp. 705–714, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Uyttenhove, L. Pilotte, I. Théate et al., “Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase,” Nature Medicine, vol. 9, no. 10, pp. 1269–1274, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. A. L. Mellor and D. H. Munn, “IDO expression by dendritic cells: tolerance and tryptophan catabolism,” Nature Reviews Immunology, vol. 4, no. 10, pp. 762–774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. D. H. Munn and A. L. Mellor, “IDO and tolerance to tumors,” Trends in Molecular Medicine, vol. 10, no. 1, pp. 15–18, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. Y.-W. He, H.-S. Wang, J. Zeng et al., “Sodium butyrate inhibits interferon-gamma induced indoleamine 2,3-dioxygenase expression via STAT1 in nasopharyngeal carcinoma cells,” Life Sciences, vol. 93, no. 15, pp. 509–515, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Iwamoto, I. S. M. Lee, R. Kido, and M. Tsubaki, “Tryptophan 2,3-dioxygenase in Saccharomyces cerevisiae,” Canadian Journal of Microbiology, vol. 41, no. 1, pp. 19–26, 1995. View at Publisher · View at Google Scholar · View at Scopus
  52. N. D. Papadopoulou, M. Mewies, K. J. McLean et al., “Redox and spectroscopic properties of human indoleamine 2, 3-dioxygenase and a His303Ala variant: implications for catalysis,” Biochemistry, vol. 44, no. 43, pp. 14318–14328, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Taniguchi, M. Sono, F. Hirata et al., “Indoleamine 2,3-dioxygenase. Kinetic studies on the binding of superoxide anion and molecular oxygen to enzyme,” The Journal of Biological Chemistry, vol. 254, no. 9, pp. 3288–3294, 1979. View at Google Scholar · View at Scopus
  54. G.-M. Jiang, Y.-W. He, R. Fang et al., “Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels,” The International Journal of Biochemistry & Cell Biology, vol. 42, no. 11, pp. 1840–1846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Lu, C. A. Bonham, F. G. Chambers et al., “Induction of nitric oxide synthase in mouse dendritic cells by IFN-γ, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis,” The Journal of Immunology, vol. 157, no. 8, pp. 3577–3586, 1996. View at Google Scholar · View at Scopus
  56. S. R. Thomas, A. C. Terentis, H. Cai et al., “Post-translational regulation of human indoleamine 2, 3-dioxygenase activity by nitric oxide,” Journal of Biological Chemistry, vol. 282, no. 33, pp. 23778–23787, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Orabona, M. T. Pallotta, C. Volpi et al., “SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 52, pp. 20828–20833, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. M. T. Pallotta, C. Orabona, C. Volpi, U. Grohmann, P. Puccetti, and F. Fallarino, “Proteasomal degradation of indoleamine 2, 3-dioxygenase in CD8+ dendritic cells is mediated by suppressor of cytokine signaling 3 (SOCS3),” International Journal of Tryptophan Research, vol. 3, pp. 91–97, 2010. View at Google Scholar
  59. J. G. Wagner and R. A. Roth, “Neutrophil migration during endotoxemia,” Journal of Leukocyte Biology, vol. 66, no. 1, pp. 10–24, 1999. View at Google Scholar · View at Scopus
  60. R. C. Bone, R. A. Balk, F. B. Cerra et al., “Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine,” Chest Journal, vol. 101, no. 6, pp. 1644–1655, 1992. View at Google Scholar
  61. E. Wirthgen, M. Tuchscherer, W. Otten et al., “Activation of indoleamine 2, 3-dioxygenase by LPS in a porcine model,” Innate Immunity, vol. 20, no. 1, pp. 30–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Galanos and M. A. Freudenberg, “Mechanisms of endotoxin shock and endotoxin hypersensitivity,” Immunobiology, vol. 187, no. 3, pp. 346–356, 1993. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Asadullah, W. Sterry, and H. D. Volk, “Interleukin-10 therapy—review of a new approach,” Pharmacological Reviews, vol. 55, no. 2, pp. 241–269, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Hwu, M. X. Du, R. Lapointe, M. Do, M. W. Taylor, and H. A. Young, “Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation,” Journal of Immunology, vol. 164, no. 7, pp. 3596–3599, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Terness, T. M. Bauer, L. Röse et al., “Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase–expressing dendritic cells: mediation of suppression by tryptophan metabolites,” The Journal of Experimental Medicine, vol. 196, no. 4, pp. 447–457, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. D. Changsirivathanathamrong, Y. Wang, D. Rajbhandari et al., “Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis,” Critical Care Medicine, vol. 39, no. 12, pp. 2678–2683, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. J.-S. Padberg, M. Van Meurs, J. T. Kielstein et al., “Indoleamine-2,3-dioxygenase activity in experimental human endotoxemia,” Experimental & Translational Stroke Medicine, vol. 4, no. 1, article 24, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. I. D. Jung, M.-G. Lee, J. H. Chang et al., “Blockade of indoleamine 2, 3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock,” The Journal of Immunology, vol. 182, no. 5, pp. 3146–3154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. W. Dabrowski, T. Kocki, J. Pilat, J. Parada-Turska, and M. L. N. G. Malbrain, “Changes in plasma kynurenic acid concentration in septic shock patients undergoing continuous veno-venous haemofiltration,” Inflammation, vol. 37, no. 1, pp. 223–234, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Wang, N. Simonavicius, X. Wu et al., “Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35,” Journal of Biological Chemistry, vol. 281, no. 31, pp. 22021–22028, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Kiank, J.-P. Zeden, S. Drude et al., “Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans,” PLoS ONE, vol. 5, no. 7, Article ID e11825, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. M. C. Barth, N. Ahluwalia, T. J. T. Anderson et al., “Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions,” The Journal of Biological Chemistry, vol. 284, no. 29, pp. 19189–19195, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. C. M. Forrest, S. R. Gould, L. G. Darlington, and T. W. Stone, “Levels of purine, kynurenine and lipid peroxidation products in patients with inflammatory bowel disease,” Advances in Experimental Medicine and Biology, vol. 527, pp. 395–400, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. M. D. Lehner and T. Hartung, “Endotoxin tolerance—mechanisms and beneficial effects in bacterial infection,” in Reviews of Physiology, Biochemistry and Pharmacology, vol. 144 of Reviews of Physiology, Biochemistry and Pharmacology, pp. 95–141, Springer, Berlin, Germany, 2002. View at Publisher · View at Google Scholar
  75. J. Li, D. F. Li, J. J. Xing, Z. B. Cheng, and C. H. Lai, “Effects of β-glucan extracted from Saccharomyces cerevisiae on growth performance, and immunological and somatotropic responses of pigs challenged with Escherichia coli lipopolysaccharide,” Journal of Animal Science, vol. 84, no. 9, pp. 2374–2381, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. M. F. Osuchowski, K. Welch, J. Siddiqui, and D. G. Remick, “Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality,” Journal of Immunology, vol. 177, no. 3, pp. 1967–1974, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. J. S. Boomer, J. M. Green, and R. S. Hotchkiss, “The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?” Virulence, vol. 5, no. 1, pp. 45–56, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Bessede, M. Gargaro, M. T. Pallotta et al., “Aryl hydrocarbon receptor control of a disease tolerance defence pathway,” Nature, vol. 511, no. 7508, pp. 184–190, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. A. De Luca, C. Montagnoli, T. Zelante et al., “Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc,” Journal of Immunology, vol. 179, no. 9, pp. 5999–6008, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. B. Dong, W. Cheng, W. Li et al., “FRET analysis of protein tyrosine kinase c-Src activation mediated via aryl hydrocarbon receptor,” Biochimica et Biophysica Acta (BBA): General Subjects, vol. 1810, no. 4, pp. 427–431, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Backlund and M. Ingelman-Sundberg, “Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases,” Cellular Signalling, vol. 17, no. 1, pp. 39–48, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. J. D. Mezrich, J. H. Fechner, X. Zhang, B. P. Johnson, W. J. Burlingham, and C. A. Bradfield, “An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells,” The Journal of Immunology, vol. 185, no. 6, pp. 3190–3198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Gandhi, D. Kumar, E. J. Burns et al., “Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3+ regulatory T cells,” Nature Immunology, vol. 11, no. 9, pp. 846–853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Venet, C.-S. Chung, H. Kherouf et al., “Increased circulating regulatory T cells (CD4+CD25+CD127-) contribute to lymphocyte anergy in septic shock patients,” Intensive Care Medicine, vol. 35, no. 4, pp. 678–686, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Stejskalova, Z. Dvorak, and P. Pavek, “Endogenous and exogenous ligands of aryl hydrocarbon receptor: current state of art,” Current Drug Metabolism, vol. 12, no. 2, pp. 198–212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. R. Thomas, “RelB and the aryl hydrocarbon receptor: dendritic cell tolerance at the epithelial interface,” Immunology and Cell Biology, vol. 91, no. 9, pp. 543–544, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. F. J. Quintana, “The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response,” Immunology, vol. 138, no. 3, pp. 183–189, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Sekine, J. Mimura, M. Oshima et al., “Hypersensitivity of aryl hydrocarbon receptor-deficient mice to lipopolysaccharide-induced septic shock,” Molecular and Cellular Biology, vol. 29, no. 24, pp. 6391–6400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. R. P. Bunaciu and A. Yen, “6-Formylindolo (3,2-b)carbazole (FICZ) enhances retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells,” Molecular Cancer, vol. 12, article 39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. B. C. DiNatale, I. A. Murray, J. C. Schroeder et al., “Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling,” Toxicological Sciences, vol. 115, no. 1, pp. 89–97, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Ploder, A. Spittler, K. Kurz et al., “Accelerated tryptophan degradation predicts poor survival in trauma and sepsis patients,” International Journal of Tryptophan Research, vol. 3, pp. 61–67, 2010. View at Google Scholar
  92. M. D. Lehner, J. Ittner, D. S. Bundschuh, N. van Rooijen, A. Wendel, and T. Hartung, “Improved innate immunity of endotoxin-tolerant mice increases resistance to Salmonella enterica serovar typhimurium infection despite attenuated cytokine response,” Infection and Immunity, vol. 69, no. 1, pp. 463–471, 2001. View at Publisher · View at Google Scholar · View at Scopus
  93. A. P. Bautista and J. J. Spitzer, “Acute endotoxin tolerance downregulates superoxide anion release by the perfused liver and isolated hepatic nonparenchymal cells,” Hepatology, vol. 21, no. 3, pp. 855–862, 1995. View at Publisher · View at Google Scholar · View at Scopus
  94. C. Yamamoto, S.-I. Yoshida, H. Taniguchi, M. H. Qin, H. Miyamoto, and Y. Mizuguchi, “Lipopolysaccharide and granulocyte colony-stimulating factor delay neutrophil apoptosis and ingestion by guinea pig macrophages,” Infection & Immunity, vol. 61, no. 5, pp. 1972–1979, 1993. View at Google Scholar · View at Scopus
  95. K. Dudek and D. Bednarek, “Cellular immune response of pigeons in the conditions of endotoxin fever and pyrogenic tolerance,” Polish Journal of Veterinary Sciences, vol. 14, no. 1, pp. 127–133, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. W. J. Frazier and M. W. Hall, “Immunoparalysis and adverse outcomes from critical illness,” Pediatric Clinics of North America, vol. 55, no. 3, pp. 647–668, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. O. M. Pena, D. G. Hancock, N. H. Lyle et al., “An endotoxin tolerance signature predicts sepsis and organ dysfunction at initial clinical presentation,” EBioMedicine, vol. 1, no. 1, pp. 64–71, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. R. S. Hotchkiss, G. Monneret, and D. Payen, “Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy,” Nature Reviews Immunology, vol. 13, no. 12, pp. 862–874, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. J.-P. Zeden, G. Fusch, B. Holtfreter et al., “Excessive tryptophan catabolism along the kynurenine pathway precedes ongoing sepsis in critically ill patients,” Anaesthesia & Intensive Care, vol. 38, no. 2, pp. 307–316, 2010. View at Google Scholar · View at Scopus
  100. H.-P. Wu, C.-C. Shih, C.-Y. Lin, C.-C. Hua, and D.-Y. Chuang, “Serial increase of IL-12 response and human leukocyte antigen-DR expression in severe sepsis survivors,” Critical Care, vol. 15, no. 5, article R224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. J. C. Schefold, J.-P. Zeden, R. Pschowski et al., “Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock,” Scandinavian Journal of Infectious Diseases, vol. 42, no. 3, pp. 164–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. C. Meisel, J. C. Schefold, R. Pschowski et al., “Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 7, pp. 640–648, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. D.-B. E. Wirthgen, LPS-induzierte aktivierung des enzyms indolamin 2, 3-dioxygenase beim schwein: physiologische konsequenzen und ihre blockade durch 1-methyltryptophan [Ph.D. thesis], Universität Rostock, Rostock, Germany, 2012.